Cyclacel Pharmaceuticals, INC

Bio Green Med Solution, Inc. announced a quarterly cash dividend of $0.15 per share for its 6% Convertible Exchangeable Preferred Stock.

Bio Green Med Solution, Inc. announced the closing of a $794,403 private placement of common stock to foreign accredited investors.

Bio Green Med Solution, Inc. has entered into a definitive agreement to acquire Future NRG Sdn. Bhd. in an all-stock transaction to create a diversified environmental and safety services platform.

Bio Green Med Solution announced first quarter 2026 financial results, highlighting progress in its fire safety business and a significant reduction in general and administrative expenses.

Bio Green Med Solution, Inc. announced its Board of Directors has declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock.

Bio Green Med Solution, Inc. announced its fourth quarter and full year 2025 financial results, highlighting a strategic pivot to fire safety and distribution activities.

Bio Green Med Solution, Inc. has completed a strategic pivot from biopharmaceuticals to fire safety and distribution, reporting a significantly reduced net loss for the nine months ended September 30, 2025, following key acquisitions and divestitures.

Cyclacel Pharmaceuticals, Inc. is undergoing a major strategic shift, liquidating its biopharma subsidiary and planning to acquire industrial assets, while facing a going concern warning and a new lawsuit.

Cyclacel Pharmaceuticals reports its Q1 2025 results, highlighting a strategic shift following the liquidation of its UK subsidiary and ongoing efforts to address going concern issues.

Cyclacel Pharmaceuticals reported its Q3 2024 financial results, highlighting ongoing clinical trials and financial challenges, including a Nasdaq delisting notice.

Cyclacel Pharmaceuticals reported its financial results for the second quarter of 2024, highlighting ongoing clinical trials and financial challenges.

Cyclacel Pharmaceuticals reported a net loss of $2.9 million for the first quarter of 2024, while highlighting progress in its clinical programs and recent financing activities.

Bio Green Med Solution, formerly Cyclacel Pharmaceuticals, Inc., completed a strategic pivot in 2025, divesting its pharmaceutical assets and acquiring a Malaysian fire safety business, Fitters Sdn. Bhd., while facing ongoing financial challenges and a preferred stock delisting.

Bio Green Med Solution, formerly Cyclacel Pharmaceuticals, is undergoing significant restructuring, including a strategic focus on its plogo clinical program and a UK subsidiary liquidation, while facing substantial doubt about its ability to continue as a going concern.

Cyclacel Pharmaceuticals' 2024 10-K filing reveals a company in strategic transition, focusing on its plogosertib program while addressing financial constraints through cost reductions and exploring strategic alternatives.

Cyclacel Pharmaceuticals has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.

Cyclacel Pharmaceuticals' 10-K filing details its capital stock, including common and preferred shares, and outlines key provisions related to dividends, voting rights, and liquidation preferences.

Bio Green Med Solution, Inc. has entered into a definitive agreement to acquire Future NRG Sdn. Bhd. in an all-stock transaction to create a diversified environmental and safety services platform.

Bio Green Med Solution's CFO and Director, Kiu Cu Seng, acquired 200,000 shares of common stock at $1.40 per share.

Bio Green Med Solution's CEO, Doris Wong Sing Ee, acquired 300,178 shares of common stock at $1.4 per share, increasing her direct beneficial ownership to 1,111,131 shares.

Bio Green Med Solution Director Yap Kim Choy exchanged various Series Warrants for 467,535 shares of common stock and disposed of 28,540 shares on November 5, 2025.

A Bio Green Med Solution director and 10% owner exchanged various series of common stock warrants for 467,535 shares of common stock.

Bio Green Med Solution's 10% owner and director, Ong Yee Lung, converted 467,535 warrants into an equal number of common stock shares.

Bio Green Med Solution, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 18, 2026, to be held via a virtual-only format.

Cyclacel Pharmaceuticals, Inc. has filed a Definitive Proxy Statement with the SEC.

A pharmaceutical company has completed a $3 million private placement of convertible preferred stock and warrants, approved by its majority shareholder, to fund operations and address significant financial uncertainties.

Cyclacel Pharmaceuticals, Inc. has filed an amendment to its definitive proxy statement, correcting its total shares outstanding and outlining proposals for its upcoming 2025 Annual Meeting of Stockholders, including director re-elections and an increase in shares for its equity incentive plan.

Cyclacel Pharmaceuticals, Inc. has announced the approval of a reverse stock split by its majority stockholder and Board of Directors, aiming to increase its share price to meet Nasdaq listing requirements and enhance marketability.

Cyclacel Pharmaceuticals is asking stockholders to approve an amendment to its 2018 Equity Incentive Plan to increase the number of shares available for grant by 4,281,987.

Cyclacel Pharmaceuticals, a clinical-stage biopharma, faces substantial doubt about its ability to continue as a going concern despite recent capital raises and a strategic acquisition of Malaysian company Fitters Sdn. Bhd.

Cyclacel Pharmaceuticals, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for the resale of common stock by existing shareholders, revealing a strategic pivot to focus solely on its plogosertib program, a significant acquisition, and ongoing financial viability concerns.

Cyclacel Pharmaceuticals has filed a registration statement for the potential resale of over 170 million shares of its common stock by selling shareholders.

Cyclacel Pharmaceuticals is launching a best efforts public offering of common stock and warrants to raise up to $5 million, primarily to address working capital needs and Nasdaq compliance issues.

Cyclacel Pharmaceuticals has filed a registration statement for the resale of up to 15,204,972 shares of its common stock by selling stockholders.

Cyclacel Pharmaceuticals, Inc. is conducting a best efforts public offering to raise up to $10 million, while facing non-compliance with Nasdaq's stockholders' equity requirement.

Datuk Dr. Doris Wong Sing Ee, CEO of Bio Green Med Solution, Inc., increased her beneficial ownership to 20.58% through a $6.3 million private purchase and an equity grant.

David E. Lazar has fully divested his beneficial ownership in Cyclacel Pharmaceuticals, Inc., reducing his stake to 0%.

Former Cyclacel Pharmaceuticals CEO David E. Lazar disclosed significant share sales and updated his beneficial ownership in an amended Schedule 13D filing.

Datuk Dr. Doris Wong Sing Ee has acquired a 70% beneficial ownership stake in Cyclacel Pharmaceuticals, Inc. for $6.3 million and has been appointed as the new Chief Executive Officer and Executive Director.

Cyclacel Pharmaceuticals, Inc. has announced significant changes in its leadership and ownership structure, including the appointment of a new Interim CEO who subsequently sold a substantial portion of his acquired shares.

Individual investor Yap Kim Choy has filed a Schedule 13G reporting an 8.47% beneficial ownership stake in Bio Green Med Solution, Inc.

Ong Yee Lung filed Amendment No. 3 to Schedule 13G, disclosing zero beneficial ownership in Bio Green Med Solution, Inc.'s common stock as of December 31, 2025.

Kua Khai Loon has filed an amendment to Schedule 13G, reporting zero beneficial ownership in Bio Green Med Solution, Inc.'s common stock.

Ong Yee Lung has reported beneficial ownership of 11.79% of Bio Green Med Solution, Inc.'s common stock, primarily through warrants.

Yap Kim Choy has reported a 14.82% beneficial ownership stake in Bio Green Med Solution, Inc., primarily through common stock and warrants.

FITTERS Diversified Berhad has reported a 7.98% beneficial ownership stake in Bio Green Med Solution, Inc., holding 279,248 shares of common stock.